ME Therapeutics Holdings Inc. News Releases

ME Therapeutics Announces It Has Engaged Lucosky Brookman LLP to Explore a Listing on the NASDAQ or NYSE

Mon, 03 Mar 2025 09:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - March 3, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announced that it has retained Lucosky Brookman LLP, a distinguished corporate finance and securities law firm, to assist in evaluating an uplisting to a senior national securities exchange such as the Nasdaq Capital...

ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo

Tue, 14 Jan 2025 09:27:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that its first therapeutic mRNA candidate from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics") has demonstrated encouraging anti-cancer activity in a mouse model...

ME Therapeutics Holdings Inc. Appoints Chief Business Officer

Fri, 25 Oct 2024 09:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - October 25, 2024) - ME Therapeutics Holdings Inc. (CSE:METX) (FSE:Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to announce the appointment of Karim Lalji as Chief Business Officer. "We are excited to be able to announce the addition of Karim Lalji as Chief Business Officer," said Salim Dhanji, PhD, Chief Executive Officer of ME...

ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update

Tue, 22 Oct 2024 06:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to update investors on the progress of our research and development and corporate development plans. G-CSF Antibody Candidate UpdateThe Company is continuing to advance our lead anti-G-CSF antibody candidate,...

ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration

Wed, 18 Sep 2024 09:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce the start of efficacy testing of the first two mRNA formulations from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics"). As previously disclosed, ME Therapeutics...

ME Therapeutics Announces New Collaboration with NanoVation Therapeutics on Advanced Therapeutic mRNA Delivery to Myeloid Cells

Mon, 08 Jul 2024 11:31:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce a strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics"). This partnership aims to test the delivery and efficacy of mRNA-based drug candidates targeted to myeloid cells.ME...

ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial

Wed, 29 May 2024 09:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company has engaged two new clinical consultants to help advance our lead anti-G-CSF antibody candidate (h1B11-12) towards a first in-human clinical trial.Dr. Kate Hanham, PhD, is a clinical trial...

ME Therapeutics to Present at Investor Clubhouse at the Canadian Open and Attend the 2024 BIO International Convention for Partnering Opportunities

Fri, 17 May 2024 09:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company will be presenting at the Investor Clubhouse during the RBC Canadian Open PGA golf tournament presented by Investor.Events. ME Therapeutics will be presenting on Friday, May 31st, 2024,...

ME Therapeutics Holdings Inc. Announces Ringing of CSE Opening Bell on April 17, 2024

Mon, 15 Apr 2024 11:10:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company's management will be ringing the opening bell for the Canadian Securities Exchange on Wednesday April 17, 2024, and invites its shareholders to tune in at 930am EST to participate in the celebration. "We are honoured to be...

ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV

Tue, 26 Mar 2024 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company's CEO, Dr. Salim Dhanji, will attend and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled to take place at the Metro Toronto Convention Centre in Toronto from April...